Innovation Policy in Cross border perspective€¦ · Maastricht Forensic Institute Clinical Trial...
Transcript of Innovation Policy in Cross border perspective€¦ · Maastricht Forensic Institute Clinical Trial...
![Page 1: Innovation Policy in Cross border perspective€¦ · Maastricht Forensic Institute Clinical Trial Centre Toxicogenomics Health Science Campus Research Valorisation Booster Biomaterials](https://reader034.fdocuments.us/reader034/viewer/2022042709/5f4183efd6339b4a0b58cf6a/html5/thumbnails/1.jpg)
Innovation Policy in Cross border perspective
“Acceleration Agenda in the Euroregion Meus Rhein/ELAT –Triangle”
Basel, 22 February 2008
Jean Severijns
(Martin Eurlings, Herman Vrehen)
![Page 2: Innovation Policy in Cross border perspective€¦ · Maastricht Forensic Institute Clinical Trial Centre Toxicogenomics Health Science Campus Research Valorisation Booster Biomaterials](https://reader034.fdocuments.us/reader034/viewer/2022042709/5f4183efd6339b4a0b58cf6a/html5/thumbnails/2.jpg)
Province of Limburg (NL)
![Page 3: Innovation Policy in Cross border perspective€¦ · Maastricht Forensic Institute Clinical Trial Centre Toxicogenomics Health Science Campus Research Valorisation Booster Biomaterials](https://reader034.fdocuments.us/reader034/viewer/2022042709/5f4183efd6339b4a0b58cf6a/html5/thumbnails/3.jpg)
A Top Technological region within Europe
� Bron: Brainport
![Page 4: Innovation Policy in Cross border perspective€¦ · Maastricht Forensic Institute Clinical Trial Centre Toxicogenomics Health Science Campus Research Valorisation Booster Biomaterials](https://reader034.fdocuments.us/reader034/viewer/2022042709/5f4183efd6339b4a0b58cf6a/html5/thumbnails/4.jpg)
�
�
��
�
��
� ��
�
�
�
�
�
��
�
�
EU Hall of Fame EU Hall of Fame candidatescandidates
�
� ??�
�
![Page 5: Innovation Policy in Cross border perspective€¦ · Maastricht Forensic Institute Clinical Trial Centre Toxicogenomics Health Science Campus Research Valorisation Booster Biomaterials](https://reader034.fdocuments.us/reader034/viewer/2022042709/5f4183efd6339b4a0b58cf6a/html5/thumbnails/5.jpg)
TECHNOLOGY CAMPUS LEUVEN
ELAT / Private R&D Capacity ( DSP ) ELAT / Private R&D Capacity ( DSP )
Ubiwave
![Page 6: Innovation Policy in Cross border perspective€¦ · Maastricht Forensic Institute Clinical Trial Centre Toxicogenomics Health Science Campus Research Valorisation Booster Biomaterials](https://reader034.fdocuments.us/reader034/viewer/2022042709/5f4183efd6339b4a0b58cf6a/html5/thumbnails/6.jpg)
Organise cross border communication and commitment !
![Page 7: Innovation Policy in Cross border perspective€¦ · Maastricht Forensic Institute Clinical Trial Centre Toxicogenomics Health Science Campus Research Valorisation Booster Biomaterials](https://reader034.fdocuments.us/reader034/viewer/2022042709/5f4183efd6339b4a0b58cf6a/html5/thumbnails/7.jpg)
2020
From Closed to Open InnovationFrom Closed to Open Innovation
Henry Chessbrough, Harvard
ResearchProjects
BoundaryFirm
DevelopmentResearch
Current Market
NewMarket
NewMarket
Philips DSM/Chemelot
Scheuten Glas
Open innovation examples/principle
![Page 8: Innovation Policy in Cross border perspective€¦ · Maastricht Forensic Institute Clinical Trial Centre Toxicogenomics Health Science Campus Research Valorisation Booster Biomaterials](https://reader034.fdocuments.us/reader034/viewer/2022042709/5f4183efd6339b4a0b58cf6a/html5/thumbnails/8.jpg)
Conclusions so far:
•Limburg integral part of Functional Border region•Aiming at highest level in Europe•Similarities open communication and open innovation approachbusiness community – governmental policy
•Respect different parts within cross border triangle/functional region•Cooperation needs to be organized (Role Province!)
Acceleration agendaLimburg
![Page 9: Innovation Policy in Cross border perspective€¦ · Maastricht Forensic Institute Clinical Trial Centre Toxicogenomics Health Science Campus Research Valorisation Booster Biomaterials](https://reader034.fdocuments.us/reader034/viewer/2022042709/5f4183efd6339b4a0b58cf6a/html5/thumbnails/9.jpg)
Power clusters in Limburg
High Tech Systems & MaterialsEnergy TechnologyHealth, Life Sciences & LeisureGreenport, Food & Nutrition
![Page 10: Innovation Policy in Cross border perspective€¦ · Maastricht Forensic Institute Clinical Trial Centre Toxicogenomics Health Science Campus Research Valorisation Booster Biomaterials](https://reader034.fdocuments.us/reader034/viewer/2022042709/5f4183efd6339b4a0b58cf6a/html5/thumbnails/10.jpg)
High Tech Systems & Materials
Energy Technology
Health, Life Sciences & Leisure
Greenport, Food & Nutrition
Combine elements of different value chainsis the real challenge, within region and cross border(according to open innovation principle)
Biomedicalmaterials
Healthy food
Solar cluster
Greenhouse of the future
![Page 11: Innovation Policy in Cross border perspective€¦ · Maastricht Forensic Institute Clinical Trial Centre Toxicogenomics Health Science Campus Research Valorisation Booster Biomaterials](https://reader034.fdocuments.us/reader034/viewer/2022042709/5f4183efd6339b4a0b58cf6a/html5/thumbnails/11.jpg)
Healthcare - pillarsTopcare - Hospital
R&D -Medical scientific research
Biomedical bus. community
Healthcare
Entrepreneurship and innovation
CardiovasculairOncologyChronical deseasesPsychological health-care
azM-Klinikum cooperationParticle Therapy CentreEuropean Vascular Centre Maastricht-AachenCentre for molecular medicineMaastricht Forensic InstituteClinical Trial CentreToxicogenomicsHealth Science CampusResearch Valorisation Booster
BiomaterialsBiopartnerCentre
![Page 12: Innovation Policy in Cross border perspective€¦ · Maastricht Forensic Institute Clinical Trial Centre Toxicogenomics Health Science Campus Research Valorisation Booster Biomaterials](https://reader034.fdocuments.us/reader034/viewer/2022042709/5f4183efd6339b4a0b58cf6a/html5/thumbnails/12.jpg)
Klinikum Aachen
AZM Maastricht
Parc Hoogveld
“Orbis” Hospital of the future
![Page 13: Innovation Policy in Cross border perspective€¦ · Maastricht Forensic Institute Clinical Trial Centre Toxicogenomics Health Science Campus Research Valorisation Booster Biomaterials](https://reader034.fdocuments.us/reader034/viewer/2022042709/5f4183efd6339b4a0b58cf6a/html5/thumbnails/13.jpg)
June 8, 2004 Signing Co-operation agreement
![Page 14: Innovation Policy in Cross border perspective€¦ · Maastricht Forensic Institute Clinical Trial Centre Toxicogenomics Health Science Campus Research Valorisation Booster Biomaterials](https://reader034.fdocuments.us/reader034/viewer/2022042709/5f4183efd6339b4a0b58cf6a/html5/thumbnails/14.jpg)
MUMC+
30715
25.768381.000
7.6
4946
Medical departmentsClinical beds
Clinical admissionsOutpatient visits
Hospital stay (days)
Employees
MUKA
34149343.000121.0007.9
6.249
![Page 15: Innovation Policy in Cross border perspective€¦ · Maastricht Forensic Institute Clinical Trial Centre Toxicogenomics Health Science Campus Research Valorisation Booster Biomaterials](https://reader034.fdocuments.us/reader034/viewer/2022042709/5f4183efd6339b4a0b58cf6a/html5/thumbnails/15.jpg)
Essential points agreement 2004
• European Centre for state-of-the-art medicine and research
• Benefit from each other‘s knowledge
• Complementary health care
• Synergy in use of resources
• Building European Centers of Reference
• Joint leadership of medical departments
• Synchronisation of research and teaching
• Network medical education and specialist training
![Page 16: Innovation Policy in Cross border perspective€¦ · Maastricht Forensic Institute Clinical Trial Centre Toxicogenomics Health Science Campus Research Valorisation Booster Biomaterials](https://reader034.fdocuments.us/reader034/viewer/2022042709/5f4183efd6339b4a0b58cf6a/html5/thumbnails/16.jpg)
Current Activities
� Feasibility study for cardiovascular merge betweenMaastricht and Aachen: Vascular Surgery, Cardiac Surgery, Cardiology
� Business plan to develop Cardiovascular Center of Excellence Maastricht-Aachen
� Venue: new building
![Page 17: Innovation Policy in Cross border perspective€¦ · Maastricht Forensic Institute Clinical Trial Centre Toxicogenomics Health Science Campus Research Valorisation Booster Biomaterials](https://reader034.fdocuments.us/reader034/viewer/2022042709/5f4183efd6339b4a0b58cf6a/html5/thumbnails/17.jpg)
![Page 18: Innovation Policy in Cross border perspective€¦ · Maastricht Forensic Institute Clinical Trial Centre Toxicogenomics Health Science Campus Research Valorisation Booster Biomaterials](https://reader034.fdocuments.us/reader034/viewer/2022042709/5f4183efd6339b4a0b58cf6a/html5/thumbnails/18.jpg)
Feasibility study (from December 2007)
� Assessment of the local, regional and national market- and competitive environment;
� Point out the strategic options of UKA and MUMC+;
� Identification and assessment of potential for synergies in patient care, especially top-referal healthcare;
� Identification and assessment of legal and structural options;
� Preparation of a time schedule, project- and action plan
![Page 19: Innovation Policy in Cross border perspective€¦ · Maastricht Forensic Institute Clinical Trial Centre Toxicogenomics Health Science Campus Research Valorisation Booster Biomaterials](https://reader034.fdocuments.us/reader034/viewer/2022042709/5f4183efd6339b4a0b58cf6a/html5/thumbnails/19.jpg)
![Page 20: Innovation Policy in Cross border perspective€¦ · Maastricht Forensic Institute Clinical Trial Centre Toxicogenomics Health Science Campus Research Valorisation Booster Biomaterials](https://reader034.fdocuments.us/reader034/viewer/2022042709/5f4183efd6339b4a0b58cf6a/html5/thumbnails/20.jpg)
Stent placement
The drug eluting stent represents the first great break-through of a combination product of biomedical materials & drugs
Source: Endeavor III clinical trials, 9 month follow-up data presented at TCT 2005; Herald-Sun 24 Feb. 2006
Cardiovascular intervention
Situation before and after placement
EXAMPLES OF RESEARCH TOPICS
![Page 21: Innovation Policy in Cross border perspective€¦ · Maastricht Forensic Institute Clinical Trial Centre Toxicogenomics Health Science Campus Research Valorisation Booster Biomaterials](https://reader034.fdocuments.us/reader034/viewer/2022042709/5f4183efd6339b4a0b58cf6a/html5/thumbnails/21.jpg)
Stents have radically changed medical treatment;next generation stents will be worked on
Old Therapy:Open heart surgery
New Therapy:Using stent
Future Therapy:Resorbable stent
Source: DSM
EXAMPLES OF RESEARCH TOPICS
![Page 22: Innovation Policy in Cross border perspective€¦ · Maastricht Forensic Institute Clinical Trial Centre Toxicogenomics Health Science Campus Research Valorisation Booster Biomaterials](https://reader034.fdocuments.us/reader034/viewer/2022042709/5f4183efd6339b4a0b58cf6a/html5/thumbnails/22.jpg)
A strong public-private partnership is committed to further strengthen the position of the Netherlands in biomedical materials
Total budget 90 m€ for a 5 year program
FOUNDING PRINCIPLES AND PARTNERS
![Page 23: Innovation Policy in Cross border perspective€¦ · Maastricht Forensic Institute Clinical Trial Centre Toxicogenomics Health Science Campus Research Valorisation Booster Biomaterials](https://reader034.fdocuments.us/reader034/viewer/2022042709/5f4183efd6339b4a0b58cf6a/html5/thumbnails/23.jpg)
We invite:Health care oriented (functional/cross border) serious and enthusiastic regions, to join forces!
Thank you for your attention !
Province of Limburg (NL)[email protected]
![Page 24: Innovation Policy in Cross border perspective€¦ · Maastricht Forensic Institute Clinical Trial Centre Toxicogenomics Health Science Campus Research Valorisation Booster Biomaterials](https://reader034.fdocuments.us/reader034/viewer/2022042709/5f4183efd6339b4a0b58cf6a/html5/thumbnails/24.jpg)
Feasibility study (from December 2007)
� Assessment of the local, regional and national market- and competitive environment;
� Point out the strategic options of UKA and MUMC+;
� Identification and assessment of potential for synergies in patient care, especially top-referal healthcare;
� Identification and assessment of legal and structural options;
� Preparation of a time schedule, project- and action plan
![Page 25: Innovation Policy in Cross border perspective€¦ · Maastricht Forensic Institute Clinical Trial Centre Toxicogenomics Health Science Campus Research Valorisation Booster Biomaterials](https://reader034.fdocuments.us/reader034/viewer/2022042709/5f4183efd6339b4a0b58cf6a/html5/thumbnails/25.jpg)